The FDA enforcement report lists a Class III recall, dated 30 September, of olanzapine 5 mg tablets in 30-count bottles manufactured by Macleods Pharmaceuticals and distributed in the US by Macleods Pharma USA. The reason given is organic and unspecified impurities above specification. The recall is listed as ongoing.
Class III is the FDA's lowest-risk category: a product unlikely to cause adverse health consequences. It concerns specific US-labelled lots, not olanzapine as a drug or the manufacturer's products in general.
Macleods is an Indian manufacturer. Whether any affected batches reached the Indian market is not stated in the notice, and no CDSCO action on this product is known.
- Patients on olanzapine should not stop it because of this notice; abrupt stopping carries a real relapse risk.
- The recall applies to specific US-labelled 5 mg bottles from one manufacturer, not to olanzapine in general.
- Class III is the FDA's lowest-risk recall tier — a quality failure, not a reported safety signal.
- If a patient brings US-sourced olanzapine from this manufacturer, ask the pharmacist to check the lot against the recall.
Why it matters
Patients who see recall headlines may stop an antipsychotic on their own, and that is the bigger risk.
Don't overread it
A Class III impurity recall is a manufacturing quality action, not evidence that olanzapine or this product caused harm.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free